FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes

INDIANAPOLIS, June 15, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company ' s (NYSE: LLY) new rapid-acting insulin indicated to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news